

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Assessment of propranolol efficacy on pediatric hemangioma

Protocol summary

Ardabil University of Medical Sciences

Summary

This study is an intervention. Patients are children under 15 years old with hemangioma. If they have hemangioma with organ malfunction, rapid progressing and large hemangioma will qualify for treatment with propranolol (mean dose 2 mg/kg twice a day for 6 month). Patients with cardiovascular disease are not involved. Their relapse will be followed up after 6 month. Control group in this study because of limitation in number of patients and absence of control group in similar study is not adopted.

Expected recruitment start date

2012-08-22, 1391/06/01

Expected recruitment end date

2013-08-23, 1392/06/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Assessment of propranolol efficacy on pediatric hemangioma

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2014041817325N1**

Registration date: **2014-06-30, 1393/04/09**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2014-06-30, 1393/04/09

Registrant information

Name

Afshin Fathi

Name of organization / entity

Ardabil University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 45 1226 1610

Email address

a.fathi@arums.ac.ir

Recruitment status

Recruitment complete

Funding source

Public title

Propranolol in treatment of hemangioma

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Patients with hemangioma under 15 years old
Exclusion criteria: Patients with cardiovascular disease; patients with history of low blood sugar; patients use another drugs last 6 months.

Age

From **1 day** old to **14 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **20**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

There is no control group in this study.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ardabil University of Medical Sciences

Street address

Daneshgah St, Janbazan Sq

City

Ardabil

Postal code

Approval date

2012-07-29, 1391/05/08

Ethics committee reference number

arums.rec.93.33

Health conditions studied

1

Description of health condition studied

Hemangioma

ICD-10 code

D18.0

ICD-10 code description

Hemangioma, any site

Primary outcomes

1

Description

Regression of hemangioma (decrease in size)

Timepoint

1 week, 6month, 1 year

Method of measurement

Watchful, sonography if needed

Secondary outcomes

1

Description

Decrease blood sugar

Timepoint

In first visit, after 1 week

Method of measurement

With glucometer

Intervention groups

1

Description

Propranolol 2 mg/kg twice a day for 6 month in case group. There is no control group.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Bu - Ali Hospital

Full name of responsible person

Dr.Afshin Fathi

Street address

Varzesh Sq. Ardabil

City

Ardabil

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ardabil University of Medical Sciences

Full name of responsible person

Parvane Naftchi

Street address

Daneshgah St, Janbazan Sq

City

Ardabil

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ardabil University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Ardabil University of Medical Sciences

Full name of responsible person

Nava Soleymani

Position

M.D, Physician

Other areas of specialty/work**Street address**

Maryam pansion, Qiam Sq

City

Ardabil

Postal code**Phone**

+98 45 1333 0633

Fax**Email**

navasoleimani@gmail.com

Web page address**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Nava Soleymani

Position

M.D, Physician

Other areas of specialty/work**Street address**

Maryam pansion, Qiam Sq

City

Ardabil

Postal code**Phone**

+98 45 1333 0633

Fax**Email**

navasoleimani@gmail.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Afshin Fathi

Position

Chairman, Specialist

Other areas of specialty/work**Street address**

Bu - Ali Hospital, Varzesh Sq

City

Ardabil

Postal code**Phone**

+98 45 1225 2251

Fax**Email**

a.fathi@arums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*